MONTPELIER, Vt. (AP) -- Vermont's attorney general says the state's share of a national prescription drug settlement will be just over $82,000.
Endo Health said last week it will pay almost $193 million to resolve claims that it improperly marketed the shingles treatment Lidoderm for unapproved uses like treating lower back pain. The Vermont attorney general's office said Tuesday that Vermont will put its share into its state Medicaid program.
Federal prosecutors said Friday that Endo Health Solutions Inc. marketed the drug for unapproved uses between 2002 and 2006.
Endo said it was pleased to resolve the issue, and it has programs in place to help it comply with the agreements. The drugmaker had already set aside $194 million to cover settlement costs.